Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,348Revenue $M103Net Margin (%)-86.5Altman Z-Score-5.5
Enterprise Value $M1,379EPS $-0.8Operating Margin %-69.6Piotroski F-Score3
P/E(ttm)--Beneish M-Score-4.2Pre-tax Margin (%)-86.3Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio1.0Cash flow > EarningsY
Price/Sales12.15-y EBITDA Growth Rate %--Current Ratio1.0Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-58.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M110ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with MACK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MACKJoel Greenblatt 2015-03-31 Buy $8.78 - $12.48
($10.82)
$ 12.2513%New holding13,433
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MACK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MACK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Nielsen Ulrik B.Director 2015-05-19Sell40,000$13.04-6.06view
Stewart Edward J.Head of Commercial 2015-05-15Sell8,000$12.33-0.65view
Sullivan William A.CFO and Treasurer 2015-05-15Sell15,000$12.37-0.97view
PORTER MICHAEL EDirector 2015-05-13Buy8,284$11.793.9view
Nielsen Ulrik B.Director 2015-04-20Sell40,000$12.88-4.89view
Stewart Edward J.SVP & Pres, Healthcare Sol 2015-04-15Sell8,000$12.79-4.22view
Sullivan William A.CFO and Treasurer 2015-04-15Sell15,000$12.87-4.82view
Fehr Gordon J.Director 2015-04-13Sell20,000$13-5.77view
Mulroy Robert J.President and CEO 2015-03-24Sell114,368$11.714.61view
PORTER MICHAEL EDirector 2015-03-24Buy5,000$11.74.7view

Press Releases about MACK :

    Quarterly/Annual Reports about MACK:

    News about MACK:

    Articles On GuruFocus.com
    Weekly CEO Sells Highlight: Starbucks Corp, KD Supply Holdings Inc, Capital One Financial Corp, Merr Dec 14 2014 

    More From Other Websites
    MERRIMACK PHARMACEUTICALS INC Financials May 15 2015
    MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... May 14 2015
    Merrimack Pharmaceuticals Announces Presentations at the 2015 American Society of Clinical Oncology... May 14 2015
    Merrimack Pharmaceuticals Announces Presentations at the 2015 American Society of Clinical Oncology... May 14 2015
    Lightning Round: Don't know why this is so cheap May 13 2015
    Merrimack Pharmaceuticals' Q1 Loss Wider Than Expected - Analyst Blog May 08 2015
    Merrimack reports 1Q loss May 07 2015
    Merrimack reports 1Q loss May 07 2015
    MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2015
    Merrimack Pharmaceuticals Reports First Quarter 2015 Financial Results May 07 2015
    Q1 2015 Merrimack Pharmaceuticals Inc Earnings Release - Time Not Supplied May 07 2015
    My Favorite Under $5 Biotech Could Soar 150% or More May 06 2015
    Merrimack Pharmaceuticals (MACK): A Miss this Earnings? - Analyst Blog May 05 2015
    Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in... May 05 2015
    Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in... May 05 2015
    Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an... May 04 2015
    PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398... May 04 2015
    Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an... May 04 2015
    Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an... May 04 2015
    Merrimack Pharmaceuticals Announces Timing of First Quarter 2015 Investor Conference Call and... Apr 28 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK